Is Liminal BioSciences Inc (LMNL) Stock Near the Top of the Biotechnology Industry?

Tuesday, July 7, 2020 11:31 AM | InvestorsObserver Analysts

The 55 rating InvestorsObserver gives to Liminal BioSciences Inc (LMNL) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 47 percent of stocks in the Biotechnology industry, LMNL’s 55 overall rating means the stock scores better than 55 percent of all stocks.

Overall Score - 55
LMNL has an Overall Score of 55. Find out what this means to you and get the rest of the rankings on LMNL!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Liminal BioSciences Inc Stock Today?

Liminal BioSciences Inc (LMNL) stock is trading at $13.40 as of 11:27 AM on Tuesday, Jul 7, a decline of -$0.29, or -2.12% from the previous closing price of $13.69. The stock has traded between $13.05 and $14.70 so far today. Volume today is light. So far 67,596 shares have traded compared to average volume of 107,701 shares.

To see InvestorsObserver's Sentiment Score for Liminal BioSciences Inc click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Should You Buy Pacific Biosciences of California Inc (PACB) Stock on Monday?

Is Fennec Pharmaceuticals Inc (FENC) Stock About to Get Hot Monday?

Do Traders View Akers Biosciences Inc (AKER) Stock's Current Trend Positively?

Will T2 Biosystems Inc (TTOO) Beat the Rest of the Stocks in the Healthcare Sector?

Is Humana Inc (HUM) Stock Worth a Buy Monday?

Related Companies